Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

Article  PubMed  Google Scholar 

Magers, M. J. et al. Staging of bladder cancer. Histopathology 74, 112–134 (2019).

Article  PubMed  Google Scholar 

Burger, M. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 63, 234–241 (2013).

Article  PubMed  Google Scholar 

Lenis, A. T., Lec, P. M., Chamie, K. & Mshs, M. D. Bladder cancer. JAMA 324, 1980–1991 https://doi.org/10.1001/jama.2020.17598 (2020).

Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle‐invasive and advanced bladder cancer in 2020. CA Cancer J. Clin. 70, 404–423 (2020).

Article  PubMed  Google Scholar 

Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022).

Article  PubMed  Google Scholar 

Ritch, C. R. et al. Use and validation of the AUA/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J. Urol. 203, 505–511 (2020).

Article  PubMed  Google Scholar 

van den Bosch, S. & Alfred Witjes, J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur. Urol. 60, 493–500 (2011).

Article  PubMed  Google Scholar 

Dinney, C. P. et al. Focus on bladder cancer. Cancer Cell 6, 111–116 (2004).

Article  CAS  PubMed  Google Scholar 

Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25–41 (2015).

Article  CAS  PubMed  Google Scholar 

Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666–675 (2001).

Article  CAS  PubMed  Google Scholar 

Yafi, F. A. et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int. 108, 539–545 (2011).

Article  PubMed  Google Scholar 

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202–205; discussion 205–206 (2005).

Galsky, M. D. et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J. Clin. Oncol. 29, 2432–2438 (2011).

Article  PubMed  Google Scholar 

Pietzak, E. J. et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur. Urol. 72, 952–959 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tran, L., Xiao, J.-F., Agarwal, N., Duex, J. E. & Theodorescu, D. Advances in bladder cancer biology and therapy. Nat. Rev. Cancer 21, 104–121 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Kouzarides, T. Chromatin modifications and their function. Cell 128, 693–705 (2007).

Article  CAS  PubMed  Google Scholar 

Shen, H. & Laird, P. W. Interplay between the cancer genome and epigenome. Cell 153, 38–55 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mills, A. A. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat. Rev. Cancer 10, 669–682 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allis, C. D. & Jenuwein, T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17, 487–500 (2016).

Article  CAS  PubMed  Google Scholar 

Cheshmazar, N. et al. Current trends in development of HDAC-based chemotherapeutics. Life Sci. 308, 120946 (2022).

Article  CAS  PubMed  Google Scholar 

Pfister, S. X. & Ashworth, A. Marked for death: targeting epigenetic changes in cancer. Nat. Rev. Drug Discov. 16, 241–263 (2017).

Article  CAS  PubMed  Google Scholar 

Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Pinkerneil, M., Hoffmann, M. J., Schulz, W. A. & Niegisch, G. HDACs and HDAC inhibitors in urothelial carcinoma — perspectives for an antineoplastic treatment. Curr. Med. Chem. 24, 4151–4165 (2017).

Article  CAS  PubMed  Google Scholar 

Kim, K. H. & Roberts, C. W. Targeting EZH2 in cancer. Nat. Med. 22, 128–134 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ler, L. D. et al. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Sci. Transl. Med. 9, eaai8312 (2017).

Article  PubMed  Google Scholar 

Andrew, R. J. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science 370, 75–82 (2020).

Article  Google Scholar 

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).

Article  ADS  Google Scholar 

Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).

Article  PubMed  Google Scholar 

Hoffmann, M. J. & Schulz, W. A. Alterations of chromatin regulators in the pathogenesis of urinary bladder urothelial carcinoma. Cancers 13, 6040 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ozawa, A. et al. Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int. 105, 1181–1186 (2010).

Article  CAS  PubMed  Google Scholar 

Pinkerneil, M. et al. Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms. Mol. Cancer Ther. 15, 299–312 (2016).

Article  CAS  PubMed  Google Scholar 

Di Cerbo, V. & Schneider, R. Cancers with wrong HATs: the impact of acetylation. Brief. Funct. Genomics 12, 231–243 (2013).

Article  PubMed  Google Scholar 

Marmorstein, R. & Zhou, M. M. Writers and readers of histone acetylation: structure, mechanism, and inhibition. Cold Spring Harb. Perspect. Biol. 6, a018762 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Koutsogiannouli, E. A. et al. Differential effects of histone acetyltransferase GCN5 or PCAF knockdown on urothelial carcinoma cells. Int. J. Mol. Sci. 18, 1449 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Jin, Q. et al. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J. 30, 249–262 (2011).

Article  CAS  PubMed  Google Scholar 

Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540–556.e525 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim, P. H. et al. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. Eur. Urol. 67, 198–201 (2015).

Article  PubMed  Google Scholar 

Pietzak, E. J. et al. Genomic differences between “Primary” and “Secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy. Eur. Urol. 75, 231–239 (2019).

Article  PubMed  Google Scholar 

Ogiwara, H. et al. Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. Cancer Discov. 6, 430–445 (2016).

Article  CAS  PubMed  Google Scholar 

Li, J. et al. A CRISPR interference of CBP and p300 selectively induced synthetic lethality in bladder cancer cells in vitro. Int. J. Biol. Sci. 15, 1276–1286 (2019).

Article  PubMed  PubMed Central